Chembio Diagnostics, Inc. (CEMI.OB) Licenses Three New Rapid-Screening Tests for Use in Brazil
On Jan. 29, Chembio Diagnostics, Inc. agreed to license its patented Dual Path Platform (DPP™) technology for use in three disease screening protocols in Brazil. The funding for the project comes from Brazil's Ministry of Health, under the auspices of the Bio-Manguinhos unit of the Oswaldo Cruz Foundation. The diseases addressed include Leishmaniasis, Leptospirosis, and stage-two positive HIV. In 2004, Chembio and Bio-Manguinhos entered into an analogous agreement based on one of Chembio's rapid result's tests for stage-one HIV. Leishmaniasis, or black fever, is a blood-borne parasitic infection caused by the sand fly. Leptospirosis, or Weil's disease, is a bacterial…